JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2011, 60(1):7-10

Study on 99mTc-MAG3 and 99mTc-DMSA renal accumulation using in vitro cellular model

Zbyněk Nový, Jana Mandíková, František Trejtnar*
Charles University in Prague, Faculty of Pharmacy, Department of Pharmacology and Toxicology, Hradec Králové, Czech Republic

Mercaptoacetyltriglycine (MAG3) and dimercaptosuccinic acid (DMSA) labelled with technetium-99m belongs to standard renal radiodiagnostics. However, the renal transport mechanisms responsible for their high renal uptake have not been fully explained. In addition, no in vitro experimental study comparing the renal uptake of these radiopharmaceuticals at the cellular level has not been performed. The investigation compared the 99mTc-MAG3 and 99mTc-DMSA renal uptake using primary rat renal cells and evaluated contribution of active and passive transport processes to the renal accumulation. The renal cells were isolated from the rat kidneys by means of the two-phase collagenase perfusion method. The used experimental model showed to be useful tool for such type of investigation. The results documented significant quantitative and qualitative differences in the accumulation of 99mTc-DMSA and 99mTc-MAG3 in the rat isolated cells. The found experimental data indicated several times higher uptake of 99mTc-MAG3 than that found in 99mTc-DMSA. 99mTc-MAG3 cellular uptake was substantially decreased when active, energy-dependent processes were inhibited. However, 99mTc-DMSA accumulation in the renal cells demonstrated only a minor dependency on energy. These findings demonstrate a very different character of the membrane transport determining 99mTc-DMSA and 99mTc-MAG3 renal accumulation.

Keywords: renal radiodiagnostics; membrane transport; bioelimination
Grants and funding:

This work was supported by grant No. 124409/FaF/C-LEK of the Grant Agency of Charles University

Received: November 30, 2010; Accepted: December 13, 2010; Published: January 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nový Z, Mandíková J, Trejtnar F. Study on 99mTc-MAG3 and 99mTc-DMSA renal accumulation using in vitro cellular model. Čes. slov. farm. 2011;60(1):7-10.
Download citation

References

  1. Piepsz, A.: Radionuclide studies in paediatric nephro-urology. Eur. J. Radiol. 2002; 43: 146-153. Go to original source... Go to PubMed...
  2. Peters, A. M.: Scintigraphic imaging of renal function. Exp. Nephrol. 1998; 6: 391-397. Go to original source... Go to PubMed...
  3. Handmaker, H., Young, B. W., Lowenstein, J. M.: Clinical experience with 99mTc-DMSA (dimercapto-succinic acid., a new renal-imaging agent. J. Nucl. Med. 1975; 16: 28-32.
  4. Brenner, M., Bonta, D., Eslamy, H., Ziessman, H. A.: Comparison of 99mTc-DMSA dual-head SPECT versus high-resolution parallel-hole planar imaging for the detection of renal cortical defects. Am. J. Roentgenol. 2009; 193: 333-337. Go to original source... Go to PubMed...
  5. Taylor, A. Jr.: Quantitation of renal function with static imaging agents. Semin. Nucl. Med. 1982; 12: 330-344. Go to original source... Go to PubMed...
  6. Taylor, A., Eshima, D., Fritzberg, A. R., Christian, P. E., Kasina, S.: Comparison of iodine-131 OIH and technetium-99m MAG3 renal imaging in volunteers. J. Nucl. Med. 1986; 27, 795-803.
  7. Itoh, K.: 99mTc-MAG3: review of pharmacokinetics, clinical application to renal diseases and quantification of renal function. Ann. Nucl. Med. 2001; 15: 179-190. Go to original source... Go to PubMed...
  8. Taylor, A., Eshima, D., Alazraki, N.: 99mTc-MAG3 - a new renal imaging agent: Preliminary results in patients. Eur. J. Nucl. Med. 1987; 12, 510-514. Go to original source... Go to PubMed...
  9. Jones D. P., Sundby G. B., Ormstad K, Orrenius S.: Use of isolated kidney cells for study of drug metabolism. Biochem. Pharmacol. 1979; 28: 929-935. Go to original source... Go to PubMed...
  10. Trejtnar, F., Nový, Z., Petřík, M., Lázníčková, A., Melicharová, L., Vaňková, M., Lázníček, M.: In vitro comparison of renal handling and uptake of two soma-tostatin receptor-specific peptides labeled with indium-111. Ann. Nucl. Med. 2008; 22: 859-867. Go to original source... Go to PubMed...
  11. Van Aubel, R. A. M. H., Masereeuw, R., Russel, F. G. M.: Molecular pharmacology of renal anion transporters. Am. J. Renal Physiol. 2000; 279: F216-F232. Go to original source... Go to PubMed...
  12. VanWert, A. L., Gionfriddo, M. R., Sweet, D. H.: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm. Drug Dispos. 2010; 31: 1-71. Go to original source... Go to PubMed...
  13. Blaufox M. D.: Transport of 99mTc-MAG3 via rat renal organic anion. J. Nucl. Med. 2004; 45: 86-88.
  14. Shikano, N., Kanai, Y., Kawai, K., Ishikawa, N., Endou, H.: Transport of 99mTc-MAG3 via rat renal organic anion transporter 1. J. Nucl. Med. 2004; 45: 80-85.
  15. Müller-Suur, R., Gutsche, H. U.: Tubular reabsorption of technetium-99m-DMSA. J. Nucl. Med. 1995; 36: 1654-1658.
  16. de Lange, M. J., Piers, D. A., Kosterink J. G., van Luijk W. H., Meijer S., de Zeeuw D., van der Hem G. K.: Renal handling of technetium-99m DMSA: evidence for glomerular filtration and peritubular uptake. J. Nucl. Med. 1989; 30: 1219-23.




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.